Primary objective
\- To study the stability of different phenotypes and endotypes of asthma at 3, 5, and 7 years of follow-up and - in MEGA COHORT and in patients on biologic treatment
Secondary objective(s)
* To study biomarkers variation post-treatment in patients with and without Nasal Polyposis * To demonstrate the existence of different subtypes of eosinophils that may be phenotypically and functionally heterogeneous * To increase the number of patients in the cohort on biologic treatment to reach at least 900 (400 over the current cohort).
Age from 18 to 80 y.o. with asthma with and without nasal polyposis based on GINA guidelines (compatible clinical symptoms+reversibility of at least 12% and 200 mL in FEV1 after the administration of 200-400 μg albuterol/salbutamol or positive methacholine test) of several severities attended at participant centres
Already in follow-up in MEGA cohort
To participate in the study
Signed informed consent
Exclusion criteria for MEGA COHORT
Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function
Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders
Patients participating in other clinical trials